Third Rock Ventures

Third Rock does not accept unsolicited business plans or pitch decks. The firm's partners identify scientific breakthroughs through their academic networks and internal ideation process, then build companies around those discoveries. Entrepreneurs and scientists are recruited as founders after the initial therapeutic hypothesis, IP strategy, and corporate structure have already been designed by Third Rock's internal team.

Third Rock operates as a company-creation platform rather than a conventional fund manager. Portfolio companies are conceived, incorporated, and housed within Third Rock's offices for the first two to three years of development. The firm staffs initial management roles internally before recruiting external CEOs and scientific leadership, effectively functioning as a biotech incubator with dedicated capital rather than an investor selecting among external startups.

Third Rock invests exclusively in biotechnology and life sciences, with particular emphasis on drug discovery, precision medicine, gene therapy, cell therapy, and genomic medicine. The firm has built companies across oncology, rare disease, immunology, and neuroscience. Investments span therapeutic modalities from small molecules to biologics to CRISPR-based gene editing.

The partnership group makes investment decisions collectively. Founding partners Mark Levin, Kevin Starr, and Robert Tepper established the firm, with partners Reid Huber and Jeffrey Tong later joining the leadership. The firm's scientific advisory network, drawn from leading academic medical centers, plays a significant role in evaluating scientific platforms during the company-formation phase.

Third Rock's primary engagement begins at company inception — a stage often preceding even a traditional seed round. The firm provides seed and Series A capital during the incubation period within its own infrastructure, then leads or participates in subsequent rounds as the company matures toward clinical trials. The firm does not typically invest in preclinical assets that have already been formed by external founders.

Yes, but typically after the incubation phase. Once a Third Rock company has reached a development milestone and installed external leadership, the firm syndicates later rounds to traditional biotech venture investors and strategic pharmaceutical partners. The initial seed and Series A rounds are generally executed solely or with a small number of aligned co-investors identified during the company-formation process.

Third Rock raises capital from institutional limited partners including university endowments, foundations, pension funds, and sovereign wealth funds. The firm is structured as a traditional venture capital partnership, not a family office or corporate venture arm. Third Rock's sixth fund closed at $1.1 billion in 2022 (per the firm's official communications).